Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Foghorn Therapeutics (FHTX) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to 193.56%.

  • Foghorn Therapeutics' EBITDA Margin rose 424000.0% to 193.56% in Q3 2025 from the same period last year, while for Sep 2025 it was 295.53%, marking a year-over-year increase of 531700.0%. This contributed to the annual value of 378.99% for FY2024, which is 1000700.0% down from last year.
  • Latest data reveals that Foghorn Therapeutics reported EBITDA Margin of 193.56% as of Q3 2025, which was up 424000.0% from 238.11% recorded in Q2 2025.
  • Foghorn Therapeutics' EBITDA Margin's 5-year high stood at 77.35% during Q3 2023, with a 5-year trough of 63617.07% in Q3 2021.
  • Its 5-year average for EBITDA Margin is 4764.7%, with a median of 523.95% in 2023.
  • Per our database at Business Quant, Foghorn Therapeutics' EBITDA Margin tumbled by -533561800bps in 2021 and then surged by 632033900bps in 2022.
  • Over the past 5 years, Foghorn Therapeutics' EBITDA Margin (Quarter) stood at 4086.96% in 2021, then surged by 84bps to 669.41% in 2022, then surged by 40bps to 399.36% in 2023, then plummeted by -73bps to 690.76% in 2024, then skyrocketed by 72bps to 193.56% in 2025.
  • Its EBITDA Margin stands at 193.56% for Q3 2025, versus 238.11% for Q2 2025 and 318.46% for Q1 2025.